Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 376
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 939.83k | N/A | 1952 |
Mr. Brian J. Lynch J.D. | Senior VP & General Counsel | 763.75k | 1.27M | 1962 |
Mr. Alex G. Howarth | Executive Officer | 757.26k | N/A | 1969 |
Mr. William J. Sibold | CEO, President & Director | N/A | N/A | 1966 |
Ms. Mardi C. Dier | CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP | N/A | N/A | 1964 |
Mr. Ronald Filippo | Chief Information Officer | N/A | N/A | N/A |
Ms. Tina E. Ventura | Chief Investor Relations Officer | N/A | N/A | N/A |
Dr. Kianoush Motesharei Ph.d. | Senior Vice President of Business & Corporate Development | N/A | N/A | 1970 |
Mr. Clint Wallace | Chief Human Resources Officer | N/A | N/A | N/A |
Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | N/A | N/A | N/A |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 8; Compensation: 7.